Abstract

  Narcolepsy is a neurological disorder that affects ability to wake and sleep. Individuals with narcolepsy have excessive, uncontrollable daytime sleepiness, cataplexy, hallucinations, sleep paralysis etc. It is divided into type 1 and 2 on the basis of cataplexy. Type 1 is autoimmune. Recently lot of research and new case reports has been published because of the association with impaired cognitive ability, poor quality of life, and risk of work, home, and car accidents. It can affect children, adolescents and even elderly. FDA and EMA approved drugs are available. In this article all published literatures of 2020 regarding narcolepsy are reviewed.

Keywords: Narcolepsy; 2020

References

1. American Academy of Sleep Medicine, International classification of sleep disorders, 3rd ed., American Academy of Sleep Medicine (2014).
2. Scammell TE. “Narcolepsy”. The New England Journal of Medicine 373 (2015): 2654-2662.
3. Dauvilliers Y., et al. “Narcolepsy with cataplexy”. Lancet 369 (2007): 499-511.
4. Overeem S., et al. “Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives”. Journal of Clinical Neurophysiology 18 (2001): 78-105.
5. Baumann CR., et al. “Challenges in diagnosing narcolepsy without cataplexy: a consensus statement”. Sleep 37 (2014): 1035-1042.
6. Longstreth WT., et al. “The epidemiology of narcolepsy”. Sleep 30 (2007): 13- 26.
7. Luca G., et al. “European Narcolepsy Network. Clinical, polysomnographic and genome- wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study”. Journal of Sleep Research 22 (2013): 482-495.
8. Bassetti CLA., et al. “Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment”. Nature Reviews Neurology 15.9 (2019): 519-539. 
9. Goldbart A., et al. “Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort”. Sleep 37 (2014): 1043-1051.
10. Partinen M., et al. “Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination”. The Lancet Neurology 13 (2014): 600-613.
11. Aran A., et al. “Elevated anti- streptococcal antibodies in patients with recent narcolepsy onset”. Sleep 32 (2009): 979-983.
12. Cvetkovic- Lopes V., et al. “Elevated tribbles homolog 2- specific antibody levels in narcolepsy patients”. Journal of Clinical Investigation 120 (2010): 713-719.
13. Luo F., et al. “Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy”. Proceedings of the National Academy of Sciences of the United States of America 115 (2018):  E12323-E12332.
14. Pedersen NW., et al. “CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens (2019): 10,837.
15. Brennan D., et al. “Antibody-Negative Paraneoplastic Limbic Encephalitis, Parkinsonism, Hypothermia, and Narcolepsy Associated with Endometrial Carcinoma”. Movement Disorders Clinical Practice7.2 (2020): 223-227. 
16. Naeimi SA., et al. “Neurodegeneration in Narcolepsy-Associated Rapid Eye Movement Sleep Behavior Disorder”. Movement Disorders Clinical Practice 7.2 (2020): 208-210. 
17. Imran Haider Zaidi SM., et al. “Level of sleep disorders among patients with chronic obstructive pulmonary disease”. Journal of Pakistan Medical Association 70.2 (2020): 259-263. 
18. Schinkelshoek MS., et al. “Daytime sleep state misperception in a tertiary sleep centre population [published online ahead of print, 2020 Jan 10]”. Sleep Medicine 69 (2020): 78-84. 
19. Chen TY., et al. “Sex and age differences in the association between anxiety disorders and narcolepsy: A nationwide population-based case control study”. Journal of Affective Disorders 264 (2020): 130-137. 
20. Lind A., et al. “Screening for autoantibody targets in post-vaccination narcolepsy using proteome arrays”. Scandinavian Journal of Immunology (2020): e12864. 
21. Xiao F., et al. “Resting-state brain network topological properties and the correlation with neuropsychological assessment in adolescent narcolepsy”. Sleep (2020): 018.
22. Franceschini C., et al. “Giving a voice to Cataplectic experience: recalls from patients with narcolepsy type 1”. Journal of Clinical Sleep Medicine (2020): 8286. 
23. Dauvilliers Y., et al. “Narcolepsy Severity Scale: A reliable tool assessing symptom severity and consequences”. Sleep (2020): 009. 
24. So JY., et al. “A Guide to Management of Sleepiness in ESKD”. American Journal of Kidney Diseases  (2020) 31066-31062. 
25. Kornum BR and Jennum P. “The case for narcolepsy as an autoimmune disease”. Expert Review of Clinical Immunology (2020): 1-3. 
26. Mari L and Shea A. “Symptomatic Narcolepsy/Cataplexy in a Dog with Brainstem Meningoencephalitis of Unknown Origin”. Journal of the American Animal Hospital Association 56.2 (2020): e56201. 
27. Schneider L and Ellenbogen J. “Images: Facial cataplexy with demonstration of persistent eye movements”. Journal of Clinical Sleep Medicine 16.1 (2020):157-159. 
28. Postiglione E., et al. “Cataplexy and ataxia: red flags for the diagnosis of DNA methyltransferase 1 mutation”. Journal of Clinical Sleep Medicine 16.1 (2020):143-147. 
29. Berntsson SG., et al. “Aniridia with PAX6 mutations and narcolepsy”. Journal of Sleep Research (2020): e12982. 
30. Ong JC., et al. “How Does Narcolepsy Impact Health-Related Quality of Life? A Mixed-Methods Study”. Behavioral Sleep Medicine (2020): 1-14. 
31. Chang ET., et al. “Risk of burn injury in patients with narcolepsy: A nationwide population-based cohort study”. Journal of Burn Care and Research (2020): 004. 
32. Adamantidis AR., et al. “A circuit perspective on narcolepsy”. Sleep (2020): 296. 
33. Quaedackers L., et al. “A Mobile App for Longterm Monitoring of Narcolepsy Symptoms: Design, Development, and Evaluation”. Journal of Medical Internet Research 8.1 (2020): e14939. 
34. Scott AJ., et al. “A comparative study of the nature and magnitude of problems sleeping in inflammatory bowel disease (IBD) compared to healthy controls”. Psychology, Health and Medicine (2020): 1-11. 
35. Carls G., et al. “Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities”. Sleep Medicine 66 (2020): 110-118. 
36. Liguori C., et al. “Pitolisant for treating narcolepsy comorbid with Parkinson's disease”. Sleep Medicine 69 (2020): 86-87. 
37. Lamb YN. “Pitolisant: A Review in Narcolepsy with or without Cataplexy”. CNS Drugs 34.2 (2020): 207-218. 
38. Lecendreux M., et al. “Pharmacokinetics of pitolisant in children and adolescents with narcolepsy”. Sleep Medicine 66 (2020): 220-226. 
39. Giannoccaro MP., et al. “Immunotherapy in Narcolepsy”. Current Treatment Options in Neurology 22.1 (2020): 2.
40. Thorpy MJ. “Recently Approved and Upcoming Treatments for Narcolepsy”. CNS Drugs 34.1 (2020): 9-27. 
41. Sousa A and Dinis-Oliveira RJ. “Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects”. Substance Abuse (2020): 1-19. 
42. Li S and Yang J. “Pitolisant for treating patients with narcolepsy”. Expert Review of Clinical Pharmacology (2020): 1-6. 
43. Sharbaf Shoar N., et al. “Dextroamphetamine-Amphetamine”. In: Stat Pearls. Treasure Island (FL): StatPearls Publishing (2020).

Citation

Citation: Rajib Dutta. “What’s New in Narcolepsy? Review of All Published Literature in 2020".Acta Scientific Neurology 3.2 (2020): 22-26.

Copyright

Copyright: © 2020 Rajib Dutta. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.